OPKO Health, Inc. (NYSE: OPK), today announced that the abstract “Top
Line Results of Once-Weekly, CTP-Modified Human Growth Hormone
(MOD-4023): Phase 2 Dose Finding Study in Children with Growth Hormone
Deficiency (GHD)” has been selected for late breaking oral presentation
at the 53rd Annual Meeting of the European Society of Paediatric
Endocrinology (ESPE) on September 20, 2014 in Dublin, Ireland.
for Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone Deficient Pediatric Population to be Presented as a Late Breaking Presentation at the European Society of Paediatric Endocrinology Conference investment picks